DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $223 | +53.8% | 10,861 | +119.6% | 0.00% | – |
| Q2 2023 | $145 | +116.4% | 4,945 | +69.3% | 0.00% | – |
| Q1 2023 | $67 | -54.7% | 2,920 | -45.5% | 0.00% | – |
| Q4 2022 | $148 | -99.9% | 5,353 | 0.0% | 0.00% | – |
| Q3 2022 | $164,000 | +4.5% | 5,353 | 0.0% | 0.00% | – |
| Q2 2022 | $157,000 | +166.1% | 5,353 | +351.3% | 0.00% | – |
| Q3 2021 | $59,000 | +25.5% | 1,186 | +42.4% | 0.00% | – |
| Q1 2021 | $47,000 | +161.1% | 833 | -22.4% | 0.00% | – |
| Q4 2019 | $18,000 | – | 1,073 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |